NextGen Biomed 2027
18 March 2027 – 19 March 2027
InterContinental London – The O2 & Magazine London, London, United Kingdom
61 speakers
Organiser (1)
Media Partners (19)
Pharma Tech Outlook · Flemingsberg Science Foundation · Life Science Leader · Bioanalysis Zone · The Medicine Maker · Bio-Equip · ADC Directory · ADC Review | Journal of Antibody-drug Conjugates · SaxoCell · Bentham Science Publishers · European Biopharmaceutical Review · Pharma Focus Europe · Onco'Zine · The Journal of Human Antibodies · International Conference Alerts · Cell and Gene · GeneTherapyNet.com · SelectScience · Nucleic Acid Insights
Sponsors (32)
GemPharmatech · Lonza AG · Ajinomoto Co., Inc. · NOF Europe GmbH · Cyagen Bioscience · WuXi Biologics · Genovis · Ribbon Bio · Phenomenex · Twist Bioscience · LenioBio GmbH · ProBio · Gyros Protein Technologies · Dapu Biotechnology (DP-BIO) · GenScript Biotech · Almac Group · A&M STABTEST Labor für Analytik und Stabilitätsprüfung GmbH · Nicoya Lifesciences · Unchained Labs Ltd · Novilytic · NanoTemper Technologies · Sunresin New Materials · evitria · Nuclera · SeromYx Systems · Atem · Charles River Discovery Research Services UK Ltd · Asimov · Wheeler Bio · Hooke Bio · The Jackson Laboratory · Aptamer Group
Association Partners (2)
Peptide Drug Hunting Consortium · The Antibody Society
Speakers (61)
- Olga Obrezanova Principal Scientist, Augmented Biologics Design, AstraZeneca
- Krzysztof Brzozka Ryvu Therapeutics
- Simon Brunner Senior Principal, Flagship Pioneering
- Alain Wagner Research Director (CNRS), BioFunctional Chemistry Lab, University of Strasbourg
- Alexia Hapeshi Associate Research Director, NanoSyrinx
- Andrew Creese Scientific Director, Analytical Development at Immunocore, Immunocore
- Aneesh Karatt Vellatt Chief Scientific Officer, Maxion Therapeutics
- Annarita Di Tacchio Research Scientist, AstraZeneca
- Antti Vuolanto CEO, Herantis Pharma
- Bradley Spencer-Dene Associate Director, GSK
- Bryce Nelson Head of Antibody Discovery, Orion Pharma
- Carolina Säll Principal Scientist, Novo Nordisk
- Christian Rohlff CEO, Oxford Biotherapeutics
- Christine Rothe CDO, iOmx Therapeutics
- Colette Johnston VP - Head of Product Platform Research, Enara Bio
- Diana Saraceni General Partner, Panakes Partners
- Ekaterina Grinko Business Innovation & Partnerships Lead Obesity/GLP-1, Novo Nordisk
- Erik Anders Vernet Sr Dir, Novo Nordisk A/S
- Federico Riccardi Sirtori Director, Head of NBE-DMPK Innovative Bioanalytics, Merck KGaA
- Giuliana Vozza Senior Scientist, AstraZeneca
- Hanne Nielsen Director, Center for Biopharmaceuticals and Biobarriers in Drug Delivery, University of Copenhagen
- Harald Mauser Technical Development Leader, Hoffmann La Roche Ltd
- Harvinder Virk Co-Founder, OnlyGoodAntibodies Community & Forum
- Hazel Mak Senior Research Scientist, AstraZeneca
- Héloïse Quillay Principal Scientist, Lab Head, Sanofi
- Hilde Stals Senior Director CMC Analytical Development, argenx
- Hilmar Warenius CEO and Co-founder, Syntherix Ltd
- Ivan Burkov Junior Partner, Inkef
- Jennifer Drew Investigator, Matrix Lead, GSK
- Joao Incio Co-founder and General Partner, Biovance Capital
- Kai Hilpert Associate Professor Infection and Immunity, London City University
- Ken Chow Health Tech Counsel, Flanders Investment & Trade
- Kim Remans Head of Protein Expression & Purification Core Facility, European Molecular Biology Laboratory (EMBL)
- Knud Jørgen Jensen Professor, Copenhagen University
- Lorenzo Albertazzi Associate Professor TU/e Department of Biomedical Engineering, Eindhoven University of Technology
- Mahendra Deonarain Chief Executive and Science Officer, Antikor
- Maria Sörhede Winzell Senior Director, Camurus
- Mariusz Olejniczak CEO, WPD Pharmaceuticals
- Mark Frigerio VP, Head of Platform Technology & Science, Bicycle Therapeutics plc
- Markus Dietrich Senior Investment Associate, Hadean Ventures
- Matthew Burrell Associate Director, AstraZeneca
- Michael Wallington Director, Oncology RWE & Epidemiology, Pfizer
- Nicolas Amiot DS Project Leader - EPM, Novartis
- Origène Nyanguile Professor, HES-SO Valais-Wallis
- Paul Sauter Senior Director Chemistry & Bioconjugation, VERAXA Biotech GmbH
- Pawel Stocki VP Research, Ossianix
- Philip Beer Chief Scientific Officer, Step Pharma
- Pini Tsukerman Chief Scientific Officer, Nectintx
- Preeti Bakrania Head of Partnerships, Platforms, LifeArc
- Rachel Evans Director Translational Medicine, AstraZeneca
- Ruud Coumans Director of Protein Chemistry and Project Leader Antibody-Drug Conjugates, Byondis
- Sergio Martínez Cuesta Principal Data and AI Scientist, Hit Discovery and Protein Sciences Bioinformatics, AstraZeneca
- Sophie Botta Gordon-Smith R&D project manager, Epitopea
- Sritama Bose Associate Director, Head of Chemistry, Nucleic Acid Therapy Accelerator, Medical Research Council (UKRI)
- Stefan Dübel Director, Technische Universitat Braunschweig
- Steve Hood Director, Oligonucleotide ADME Strategy, DMPK, GSK
- Thomas Jostock Associate Director, Novartis Pharma
- Tina Matin Senior Scientist II, Protein Engineering, Sanofi
- Tomas Leek Senior Director, AstraZeneca
- Vaios Karanikas Translational Biomarker Sciences Group Head, Roche
- Winston Haynes Vice President, Computational Sciences and Engineering, LabGenius